YUHAN CORPORATION |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 72,300 KRW | -1.23% |
|
+5.55% | +5.09% |
| Apr. 24 | Korean Sugar Imports Plunge 14% as Diabetes Cases Surge | MT |
| Mar. 07 | Yuhan Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Yuhan Corp is a Korea-based company mainly engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through three segments. The Pharmaceutical segment is engaged in the production and sale of non-prescription drugs including anti-inflammatory drugs, as well as prescription drugs such as drugs for hepatitis, diabetes, and hypertension. The Life and Health segment is involved in the production and sale of household goods and animal healthcare (AHC) products, including bleach, antibacterial agents. The Overseas Business segment supplies raw drugs to domestic and overseas markets. The Company also sells licenses. The Company distributes its products in domestic and overseas markets such as Europe, Asia and United States.
Sector
Pharmaceuticals
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
72,300
KRW
Average target price
85,674
KRW
Spread / Average Target
+18.50%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +5.09% | 3.92B | |
| +4.23% | 70.78B | |
| +10.72% | 9.15B | |
| -15.34% | 4.84B | |
| +34.54% | 4.22B | |
| +20.57% | 2.55B | |
| -28.33% | 2.24B | |
| -24.15% | 2.26B | |
| +6.23% | 1.92B | |
| -0.50% | 1.64B |
- Stock Market
- Equities
- A000100 Stock
- News Yuhan Corporation
- Market Chatter: Yuhan, Samsung Bioepis Enter Partnership to Market Humira’s Biosimilar in South Korea
